In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report), with a price target of $23.00. The company’s shares closed last Friday at $14.67.
According to TipRanks, Raymond is a 4-star analyst with an average return of 3.6% and a 48.80% success rate. Raymond covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.
Deciphera Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.63, which is a 54.26% upside from current levels. In a report released on April 8, JMP Securities also reiterated a Buy rating on the stock with a $23.00 price target.
DCPH market cap is currently $1.19B and has a P/E ratio of -6.40.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DCPH in relation to earlier this year. Most recently, in February 2024, Brightstar Associates LLC, a Major Shareholder at DCPH bought 914,001.00 shares for a total of $9,140.01.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals (DCPH) Company Description:
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
